Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024665 | 0.85 | NPC1 (0.48) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4031003 | 0.83 | MAPT (0.38) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4027203 | 0.83 | DHFR (0.40) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL4846761 | 0.79 | RAB9A (0.46) | ALDH1A1MAPTKMT2ATDP1LMNA | |
| SCHEMBL4022131 | 0.74 | MAPT (0.47) | ALDH1A1MAPTKMT2ALMNAMAPK1 | |
| SCHEMBL4026433 | 0.71 | GAA (0.40) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4027817 | 0.71 | L3MBTL1 (0.39) | LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL4029331 | 0.69 | GAA (0.46) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL880841 | 0.69 | ALDH1A1 (0.51) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL4024101 | 0.69 | MAPT (0.49) | ALDH1A1MAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499610-B1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HITEK CO LTD (KR) | 2009-01-21 | — | — | EP | disclosed |
| US-7414068-B2 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2008-08-19 | — | — | US | disclosed |
| EP-1499610-A4 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2006-05-24 | — | — | EP | disclosed |
| US-20060035948-A1 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2006-02-16 | — | — | US | disclosed |
| EP-1499610-A2 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dongbu Hannong Chemical Co., Ltd. (KR) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003084464-A2 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO., LTD (KR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035948-A1 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | TH, TNNI3, NOS3 | ALDH1A1 430/4885MAPT 1509/4885MEN1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.